DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 2,008 filers reported holding DANAHER CORPORATION in Q1 2022. The put-call ratio across all filers is 1.38 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,708,522 | +110.4% | 12,358 | +130.3% | 0.04% | +91.3% |
| Q2 2023 | $1,287,600 | +12.5% | 5,365 | +18.1% | 0.02% | 0.0% |
| Q1 2023 | $1,144,513 | +3.7% | 4,541 | +9.2% | 0.02% | 0.0% |
| Q4 2022 | $1,103,881 | +47.2% | 4,159 | +43.3% | 0.02% | +64.3% |
| Q3 2022 | $750,000 | -6.8% | 2,903 | -8.5% | 0.01% | -30.0% |
| Q2 2022 | $805,000 | +15.0% | 3,172 | +32.8% | 0.02% | +66.7% |
| Q1 2022 | $700,000 | +56.2% | 2,388 | +75.2% | 0.01% | +71.4% |
| Q4 2021 | $448,000 | -31.2% | 1,363 | -36.3% | 0.01% | -41.7% |
| Q3 2021 | $651,000 | +213.0% | 2,140 | +176.5% | 0.01% | +200.0% |
| Q2 2021 | $208,000 | -88.1% | 774 | -90.1% | 0.00% | -91.1% |
| Q1 2021 | $1,753,000 | +33.3% | 7,786 | +31.5% | 0.04% | +4.7% |
| Q4 2020 | $1,315,000 | +167.8% | 5,921 | +31.1% | 0.04% | +87.0% |
| Q3 2018 | $491,000 | +10.3% | 4,517 | 0.0% | 0.02% | -25.8% |
| Q2 2018 | $445,000 | +0.7% | 4,517 | 0.0% | 0.03% | +3.3% |
| Q1 2018 | $442,000 | +5.2% | 4,517 | 0.0% | 0.03% | +7.1% |
| Q4 2017 | $420,000 | -99.3% | 4,517 | -99.4% | 0.03% | -86.5% |
| Q3 2017 | $60,621,000 | +7.0% | 706,691 | +5.3% | 0.21% | +11.3% |
| Q2 2017 | $56,633,000 | +203.2% | 671,103 | +207.3% | 0.19% | +226.3% |
| Q1 2017 | $18,678,000 | -76.7% | 218,366 | -78.8% | 0.06% | -77.9% |
| Q4 2016 | $80,151,000 | +3.1% | 1,029,678 | +3.9% | 0.26% | +2.0% |
| Q3 2016 | $77,719,000 | +13.1% | 991,442 | +9.9% | 0.25% | -4.5% |
| Q2 2016 | $68,712,000 | +68.3% | 901,861 | +109.5% | 0.26% | +37.3% |
| Q1 2016 | $40,835,000 | -16.5% | 430,467 | -18.3% | 0.19% | -15.4% |
| Q4 2015 | $48,921,000 | +3.7% | 526,708 | -4.9% | 0.23% | -2.6% |
| Q3 2015 | $47,186,000 | -2.6% | 553,762 | -2.2% | 0.23% | +3.1% |
| Q2 2015 | $48,451,000 | -13.9% | 566,067 | -14.6% | 0.23% | -9.2% |
| Q1 2015 | $56,247,000 | -5.9% | 662,494 | -6.0% | 0.25% | -2.0% |
| Q4 2014 | $59,752,000 | +8.1% | 704,615 | -3.1% | 0.26% | +8.5% |
| Q3 2014 | $55,275,000 | -0.4% | 727,477 | +3.2% | 0.24% | 0.0% |
| Q2 2014 | $55,490,000 | +50.5% | 704,792 | +43.3% | 0.24% | +58.8% |
| Q1 2014 | $36,880,000 | +76.5% | 491,698 | +81.6% | 0.15% | +72.1% |
| Q4 2013 | $20,900,000 | -38.1% | 270,728 | -44.4% | 0.09% | -41.9% |
| Q3 2013 | $33,742,000 | – | 486,751 | -2.2% | 0.15% | – |
| Q2 2013 | $0 | – | 497,857 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |